Compare Western Union Co (WU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Western Union Co vs State Street SPDR S&P Biotech ETF — how do they compare? Western Union Co trades at $7.1 (market cap $2.20B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Western Union Co pays a 13.33% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Western Union Co nearer its low. Which is the better fit depends on your goals.
| WU | XBI | |
|---|---|---|
Market Cap | $2.20B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $10.28 | $164.28 |
52-Week Low | $6.36 | $86.92 |
Enterprise Value | $2.10B | — |
Dividend Yield | 13.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Western Union (WU) trades at $7.13, up 1.42% with bearish technical signals and mixed fundamentals. The stock shows attractive valuation metrics with P/E of 5.69 and P/S of 0.56, but faces revenue decline from $4.5B in 2022 to $4.05B in 2025. Recent Q2 2026 earnings missed estimates at $0.31 vs. $0.42 expected, continuing a trend of earnings underperformance despite strong profitability margins.
The outlook remains challenging with declining revenue trends and bearish analyst sentiment (57% Hold, 31% Sell). Key risks include competitive pressure in money transfer services and digital transition challenges. The consensus price target of $7.14 offers minimal upside potential from current levels, suggesting limited near-term growth prospects for investors.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
